September 30th 2025 1:00 PM - 2:00 PM (ET)
Healthcare Policy: Pharmaceutical DTC Advertising — Attorney Paul Schiff Berman on Its Legality
Tickers: REGN, MRK, BMY, AZN:LN, LLY, NOVOB:DC, PFE, SAN:FP, ROG:SW, NOVN:SW, VEEV, HIMS, DOCS
Sector: Healthcare
Agenda
- To what extent does the FDA have the authority to regulate pharmaceutical DTC advertising? What is the distinction between regulating advertising and restricting constitutional free speech?
- What is the process and timeline for the FDA to eliminate the adequate provision rule? What arguments might pharmaceutical companies use to challenge a new rule, and what is the likely outcome?
- What are some views on the proposed legislation in Congress aimed at curtailing pharmaceutical DTC advertising?
- Do the same advertising standards that apply to pharmaceutical manufacturers also apply to drug compounders? To what extent are drug compounders' advertisements regulated by the FTC compared to the FDA?
Advisor
Walter S. Cox Professor of Law, George Washington University Law School
Moderator
Sunny SaxenaView All Upcoming Events & Teleconferences Modify Email Preferences
You will be charged for any event to which you RSVP (subject to the unit cost referenced in your Guidepoint agreement). You will receive access to the recording and transcript for any teleconference to which you RSVP within two business days, whether or not you attend the live presentation.
Guidepoint events are by invitation only. You are NOT PERMITTED to forward this registration to any third-party outside of your organization without Guidepoint's prior written consent.
Navigate To A New Experience X
View event sign ups in our Insights Library Portal and discover more of the content that fuels your research.